FILTER

Refine your search with the following facets to narrow down your results.

10 Current news of EpiStem

Epistem Announces a Three Year Collaboration with GlaxoSmithKline in Fibrosis Research

15-Mar-2012 - Epistem Plc announced a three year biomarker collaboration with GlaxoSmithKline in the field of fibrosis research. The collaboration will focus on identifying key characteristics of diseased fibrotic tissue on which Epistem will apply its proprietary RNA-Amp(TM) technology to facilitate building ...

biomarker gene expression GlaxoSmithKline

Epistem Announces Partnership with The University of Manchester

14-Nov-2011 - Epistem plc announce a partnership with Dr Matthew Hardman at The University of Manchester in which novel preclinical models for cutaneous wound healing, developed within Dr Hardman’s laboratory, will be transferred to Epistem.Epistem and The University of Manchester have been awarded a Knowledge ...

inflammatory bowel disease wound healing

Epistem: Human Deoxyribonucleic acid (DNA) Identification collaboration

07-Oct-2011 - Epistem announced the formation of a human DNA Identification collaboration with the National Policing Improvement Agency (NPIA). Epistem and the NPIA will be evaluating Epistem’s Genedrive™ molecular device as part of the NPIA’s ADAPT programme (Accelerated DNA Profiling Technology ...

deoxyribonucleic acid

Epistem Announces Tuberculosis Diagnostic Collaboration

04-Jul-2011 - Epistem plc announced the formation of a Tuberculosis (TB) diagnostic collaboration with Xcelris Laboratories, one of India's Genomics research and Diagnostic testing companies. Epistem and Xcelris will be evaluating Epistem's Genedrive(TM) molecular device as part of India's RNTCP (Revised ...

diagnostic tests India tuberculosis

Epistem Announces Collaboration With sanofi-aventis

21-Mar-2011 - Epistem plc announced a collaboration with sanofi-aventis U.S. Inc. relating to the use of Epistem's proprietary biomarker gene expression profiling and immunohistochemistry technologies. Under the terms of the agreement sanofi-aventis has entered into a 3 year collaboration with Epistem to ...

biomarkers oncology Sanofi-aventis

Epistem Awarded Further Long Term Funding for NIH Biodefence Programme

05-Nov-2010 - Epistem plc announced that it has been reappointed for up to five years to provide preclinical testing services as a subcontractor to the U.S. National Institutes of Health's (NIH) Radiation/Nuclear Medical Countermeasure Product Development Support Services Contract, which has been awarded to ...

allergies biology drug screening +4

Epistem Announce Agency Agreement With Veritas Japan

03-Sep-2010 - Epistem plc announced that its Contract Research Services division has entered into an agreement with the Veritas Corporation to exclusively market and distribute Epistem's scientific research services in Japan. The Veritas agreement will provide Epistem with a sales and marketing presence in ...

contract research drug development services

Epistem's Biomarker Division Gains GCLP Accreditation

08-Jun-2010 - Epistem plc has announced that their Biomarker Division has been awarded Good Clinical Laboratory Practice (GCLP) accreditation status. The Biomarker Division conducts gene expression analysis to support clinical drug development programs within pharmaceutical and biotechnology organisations, ...

accreditation biomarker biomarkers +7

Epistem’s Biomarker Focus in the US

21-Oct-2009 - Epistem Plc will open a US office based in Boston, MA to increase its presence in the all important North American Market. The US office (‘Epistem Inc’) will support the commercialisation of the recently launched proprietary GenetRxTM biomarker platform in oncology. Epistem’s biomarker ...

cooperations drug development laboratory services +1

Epistem announce collaboration with Humanetics Corporation

28-Jul-2008 - Epistem announced that it has been selected by Humanetics Corporation of Minnesota, USA, to provide specialised preclinical efficacy testing services for agents likely to protect the intestinal epithelium from subsequent radiation damage. Under an appropriation award to Humanetics from the US ...

contract research inflammatory bowel disease oncology +3